semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-85.0,  Chronic Obstructive Pulmonary Disease Patients with COPD eligible to moderate COPD according to the of gold GOLD (Global Initiative for Chronic Obstructive Lung Disease) and who had post-bronchodilator spirometry results in the last year of FEV1 (forced expiratory volume in one second) / FVC (forced vital capacity) <0.7 and FEV1 between 50% and 80% of previsto Besides being former smokers for at least three months and were clinically stable, no disease exacerbation in the past three months Accompanied by a pulmonologist Age between 40-85 years They are not practicing physical activity Without cardiovascular or orthopedic disease that makes it impossible to perform the exercises of the RP protocol Without presenting other comorbidities that put them at risk during the exercises  Use of bronchodilators and oral theophylline, oxygen therapy or corticosteroids  Patients who have musculoskeletal comorbidities that interfere with walking or performing upper extremity exercises lower peripheral saturation decrease of oxygen lower than 90% during the 6 minute walk test (six) minutes Presenting difficulty of cognitive understanding of body awareness and the ability to recall information for the questionnaire responses applied in the evaluation and re-evaluation in addition to this also children, adolescents and legally incapable
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma COPD for Asthma History consistent with asthma: episodic wheezing, shortness of breath, or cough Airway lability recognized by at least 12% improvement in Forced Expiratory Volume (FEV1) after 2 puffs of beta2 agonist Age >18yrs FEV1 >40% predicted Never smoker, current smoker, or quit smoking ≥5 years ago for COPD History consistent with COPD: dyspnea with exertion, productive cough, progressive course Smoking history of at least 20 pack years Current smoker or quit smoking ≥5 years ago Age >18yrs FEV1: Forced Vital Capacity (FVC) ratio < 0.70 following 2 puffs of albuterol  for Asthma Other respiratory illness other than asthma Chronic infectious process Significant other medical illness Inability to consent Pregnancy for COPD Other respiratory illness other than COPD Chronic infectious process Significant other medical illness Inability to consent
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Severe Acute Respiratory Infection A history of feverishness or measured fever of ≥ 38 deg C Cough Dyspnoea (shortness of breath) OR Tachypnoea  • No
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 45.0-80.0,  Benign Prostatic Hyperplasia (BPH) Subject has diagnosis of lower urinary tract symptoms due to benign prostatic enlargement causing bladder outlet obstruction Age from 45 to 80 years Subject has medical record documentation of a prostate volume between 30mL and 80mL (inclusive) by transrectal ultrasound (TRUS). (If TRUS testing documentation is available from less than 180 days prior to the informed consent date and the prostate volume is between 30mL and 80mL, it may be used for the inclusion/  Subject has an International Prostate Symptom Score (IPSS) score greater than or equal to 12 measured at the baseline visit Subject has medical record documentation of a maximum urinary flow rate (Qmax) less than 15mL/s. (If uroflow testing documentation is available within 90 days prior to the informed consent date, and the sample is greater than or equal to 125mL, and the Qmax is less than 15mL/s it may be used for the inclusion/ Subject has a serum creatinine that is within the normal range for the laboratory at the study center (or documentation of clinical insignificance in the subject's medical record by the investigator if outside the normal range) and measured ≤ 30 days prior to the date of surgery History of inadequate response, contraindication, or refusal to medical therapy Body Mass Index (BMI) ≥ 42 History of prostate cancer or current/suspected bladder cancer Prostate cancer should be ruled out before participation to the satisfaction of the investigator if Prostate-Specific Antigen (PSA) is above acceptable thresholds Subjects with a history of actively treated bladder cancer within the past two (2) years Bladder calculus or clinically significant bladder diverticulum (e.g., pouch size >20% of full bladder size) Active infection, including urinary tract infection
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Healthy Volunteers Cohorts 1 to 13 (all subjects) Subject must be a man or woman aged between 18 to 65 years of age, inclusive: Women of non-childbearing potential only defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile or permanently sterilised. Men who are willing and able to use suitable contraception methods listed in Section 4.5.1, from the time of the first dose of study medication until 90 days after discharge from the study A woman must have a negative serum β human chorionic gonadotropin (β-hCG) test at screening and a negative urine pregnancy test at Day -1 Subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol Each subject must sign an informed consent form (ICF) Body weight ≥50 kg and BMI within the range 19-29 kg/m2 (inclusive) Average QTcF <450 msec at screening and Day -1 visits Vital sign assessments within normal ranges. Cohorts 1 to 11 and 13 (healthy volunteers and smokers only) Healthy as determined by a physician, based on a full medical evaluation including medical history, physical examination, laboratory tests  Cohorts 1 to 13 (all subjects) Upper or lower respiratory tract infection within 4 weeks of the screening visit and prior to randomisation A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result at screening Current or chronic history of liver disease, or known hepatic or biliary abnormalities Positive test for alcohol or drugs of abuse Use of prescription medications within 14 days prior to the screening visit and agree not to use prescription medications throughout the duration of the study Are taking over the counter (OTC) medications for 14 days prior to Screening visit and agree to refrain from taking such medications throughout the study History of regular alcohol consumption within 6 months of the study Definite or suspected history of drug or alcohol abuse within the previous 5 years A positive test for HIV antibody
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Respiratory Diseases Age: ≥ 18 years old Gender: Female and Male Signed informed consent Out-patients at the Pham Ngoc Thach Hospital One or several symptoms suggesting chronic respiratory disease (cough, chest tightness, wheezing, dyspnoea, sputum), lasting 3 months or more Lung function defect (FEV1/FVC < 0,7 or FEV1 < 80% PV with FEV1/FVC > 0,7 or FEV1> 80% PV and FEV1/FVC > 0,7 with a decrease of DLCO (< 80% PV). FEV1: Forced Expiratory Volume in 1 Second FVC : Forced Vital Capacity PV: predicted value DLCO: Diffusing Capacity of the Lung for Carbon Monoxide Patients are able to stop anti-histamine 5 days before evaluation Patients are able to stop bronchodilator treatment before performing lung function test according to standard practice (immediate release theophylline: 24 hours, long acting β2-agonist: 12 hours, short acting β2-agonist: 6 hours and short acting anticholinergic: 8 hours)  The patients do not agree to participate in the study Presence of one or more chronic diseases: HIV, active tuberculosis, hypertension, heart failure, diabetes, low BMI (<18.5) or mental health disorders Treatment with B-blockers, drugs of vascular/heart disease
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Automated Measurement of Vital Signs Adult male and female hospital in-patients Vital signs considered 'stable' by clinical caregivers  Pediatric patients Female patients who are pregnant Patients with internal or external defibrillators Patients who have undergone surgery and still have a fresh incision on the chest Patients with skin damage on the chest such as burns, irritation, infections, wounds, etc Patients who are in the Critical Care Unit (CCU) Patients who otherwise satisfy any of the contraindications associated with the VSP system
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vital Signs Adult male and female in-patients with vital signs considered 'stable' by clinical caregivers  Pediatric patients Female patients who are pregnant Patients with internal or external defibrillators Patients who have undergone surgery and still have a fresh incision on the chest Patients with skin damage on the chest such as burns, irritation, infections, wounds, etc Patients in the Critical Care Unit (CCU) Patients who otherwise satisfy any of the contraindications associated with the VSP system
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hypersensitivity Pneumonitis Airway Disease Small Diagnosis of chronic hypersensitivity pneumonitis confirmed by patients with known exposure to antigen, tomographic and absence of other diagnoses confirmation with histology obtained by transthoracic biopsy, surgical biopsy or bronchoalveolar lavage with lymphocytosis above 30% Age between 18 to 75 years Clinically stable (no exacerbations or hospitalizations related to the underlying disease) for at least 6 weeks Compliance with signing an informed consent for participation in the project  Patients with FEV1 and / or DLCO <30% predicted Patients using supplemental oxygen Previous diagnosis of asthma or COPD Pregnant women Musculoskeletal disorders that limit exercise Another medical condition that might interfere with the execution of tests Current or past smoking history with tobacco intake greater than 30 pack-years Severe heart disease functional class New York Heart Association (NYHA) III-IV) and / or decompensated hear failure
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 20.0-90.0,  Chronic Obstructive Pulmonary Disease (COPD) Asthma Asthma With Chronic Obstructive Pulmonary Disease Bronchiectasis Inactive Tuberculosis of Lung Chronic Obstructive Airway Disease COPD Postbronchodilator FEV1/FVC < 0.7 AND chronic respiratory symptom  - Asthma Never smoker or <5PY of smoking history AND Recurrent episodes of asthma symptoms (wheezing, dyspnea, chest tightness, cough) AND (either Positive BDR OR positive metacholine/mannitol/exercise provocation test) - ACOS COPD AND Asthma (regardless of smoking status)
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 75.0-999.0,  Acute Dyspnea Admission to the Emergency Department Age ≥ 75 years AND of acute dyspnoea Breathe rate ≥ 25 cycles/minute or PaO2 ≤ 70 mmHg or SpO2 ≤ 92% in room air or PacO2 ≥ 45 mmHg and pH ≤ 7.35 AND Electrocardiogram in sinus rhythm at admission  None
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Chronic Obstructive Pulmonary Disease Provide informed consent Males not donating sperm and using adequate contraception or females who are surgically sterile or postmenopausal lead ECG showing:Heart rate 45 to 90 bpm, QTcF≤450 msec, QRS ≤120 msec, PR interval ≤220 msec, no clinically significant abnormality Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly BMI 18 to 33 kg/m2 with a minimum weight of 45 kg COPD diagnosis for at least 1 year and clinically stable COPD in previous 4 weeks Demonstrates reversibility to bronchodilator (two puffs of salbutamol followed by two puffs of ipratropium) via spirometry Post-bronchodilator FEV1/forced vital capacity (FVC) ratio of ≤0.70 Post-bronchodilator FEV1 ≥40 % and ≤80% of predicted normal ≥150 mL increase from pre-bronchodilator FEV1  History of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation COPD exacerbation requiring oral steroids in the previous 3 months History of one or more hospitalisations for COPD in the previous 12 months Respiratory tract infection (both upper and lower) treated with antibiotics in previous 12 weeks Evidence of cor pulmonale or clinically significant pulmonary hypertension Other respiratory disorders Previous lung resection or lung reduction surgery Oral therapies for COPD in the previous 3 months and throughout the study Drug or alcohol abuse in the past 3 years Received an experimental drug within 3 months or five half lives, whichever is longer
Patient description: The patient is a 60-year-old Spanish man presenting with shortness of breath about a day before. The symptoms began acutely and progressively worsened. He is a known case of COPD since 2 years ago. The spirometry revealed post-bronchodilator FEV1/FVC = 60% of predicted values. He smokes 20 cigarette per day. His past medical history is remarkable for BPH and he is using Flomax for that. His family history is positive for HTN in his brother. His medication includes Duo-Neb inhaled q4 hr PRN, Vit D3 1000 units per day and Flomax for his PBH. He is an obese man who is acutely ill but oriented and conscious. The vital signs are as bellow: BP: 135/80 RR: 25/min HR: 75 bpm BMI: 40 O2sat: 90%

Clinical trial eligibility criteria: eligible ages (years): 40.0-69.0,  Prostate Cancer Prostate Biopsy Genetic Counselling Genetic Markers Men with either: 1. A positive family history of PrCa defined as Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age 2. Of African or Caribbean ancestry defined as: Both parents and all 4 grandparents from that origin Age 40 years WHO performance status 02 (see Appendix A) Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow up schedule  Previous cancer with a life expectancy of less than five years Previous PrCa Negative biopsy within one year before recruitment Comorbidities making prostate biopsy risk unacceptable (Warfarin or Clopidogrel) Contraindications to having an MRI (pacemakers, aneurysm clips, claustrophobia)